TITLE

Neuroprotection in Multiple Sclerosis: A Therapeutic Approach

AUTHOR(S)
Maghzi, Amir-Hadi; Minagar, Alireza; Waubant, Emmanuelle
PUB. DATE
October 2013
SOURCE
CNS Drugs;2013, Vol. 27 Issue 10, p799
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is pathologically characterized by inflammatory demyelination and neurodegeneration. Axonal damage, along with neuronal loss, occurs from disease onset and may lead to progressive and permanent disability. In contrast with the inflammatory pathways, the molecular mechanisms leading to MS neurodegeneration remain largely elusive. With improved understanding of these mechanisms, new potential therapeutic targets for neuroprotection have emerged. We review the current understanding of neurodegenerative processes at play in MS and discuss potential outcome measures and targets for neuroprotection trials.
ACCESSION #
90429115

 

Related Articles

  • Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms. Levin, Michael C.; Douglas, Joshua N.; Meyers, Lindsay; Sangmin Lee; Yoojin Shin; Gardner, Lidia A. // Degenerative Neurological & Neuromuscular Disease;2014, Vol. 4, p49 

    Multiple sclerosis (MS) is a complex autoimmune disease that impairs the central nervous system (CNS). The neurological disability and clinical course of the disease is highly variable and unpredictable from one patient to another. The cause of MS is still unknown, but it is thought to occur in...

  • Disease Modifying Therapy in Multiple Sclerosis. Williams, U. E.; Oparah, S. K.; Philip-Ephraim, E. E. // ISRN Otolaryngology;2014, p1 

    Multiple sclerosis is an autoimmune disease of the central nervous system characterized by inflammatory demyelination and axonal degeneration. It is the commonest cause of permanent disability in young adults. Environmental and genetic factors have been suggested in its etiology. Currently...

  • Enlargement of Cerebral Ventricles as an Early Indicator of Encephalomyelitis. Lepore, Stefano; Waiczies, Helmar; Hentschel, Jan; Ji, Yiyi; Skodowski, Julia; Pohlmann, Andreas; Millward, Jason M.; Paul, Friedemann; Wuerfel, Jens; Niendorf, Thoralf; Waiczies, Sonia // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Inflammatory disorders of the central nervous system such as multiple sclerosis and acute disseminated encephalomyelitis involve an invasion of immune cells that ultimately leads to white matter demyelination, neurodegeneration and development of neurological symptoms. A clinical diagnosis is...

  • Neuromyelitis optica: multiple sclerosis variant or independent disease? Mutch, Kerry // International Journal of Ophthalmic Practice;June /July 2012, Vol. 3 Issue 3, p114 

    Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder of the central nervous system. Relapses typically affect the optic nerves (uni/bilateral optic neuritis) and the spinal cord (myelitis). Disability often accrues with relapses and can occur early in the disease course. While...

  • CNS-targeted LIF Expression Improves Therapeutic Efficacy and Limits Autoimmune-mediated Demyelination in a Model of Multiple Sclerosis. Slaets, Helena; Hendriks, Jerome J.A.; Van den Haute, Chris; Coun, Frea; Baekelandt, Veerle; Stinissen, Piet; Hellings, Niels // Molecular Therapy;Apr2010, Vol. 18 Issue 4, p684 

    Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) with an inflammatory and a neurodegenerative component. The neuropoietic cytokine leukemia inhibitory factor (LIF) is expressed in MS lesions, but its effect on lesion development is far from understood. LIF...

  • Control of autoimmune CNS inflammation by astrocytes. Rothhammer, Veit; Quintana, Francisco // Seminars in Immunopathology;Nov2015, Vol. 37 Issue 6, p625 

    Multiple sclerosis is a neurologic disease caused by immune cell infiltration into the central nervous system, resulting in gray and white matter inflammation, progressive demyelination, and neuronal loss. Astrocytes, the most abundant cell population in the central nervous system (CNS), have...

  • Concurrence of multiple sclerosis and brain tumors. Plantone, Domenico; Renna, Rosaria; Sbardella, Emilia; Koudriavtseva, Tatiana // Frontiers in Neurology;Mar2015, Vol. 6, p1 

    The article discusses research which examined the concurrence of multiple sclerosis (MS), a chronic demyelinating inflammatory disease of the central nervous system (CNS), and brain tumors. Topics discussesd include the differential diagnosis between MS and brain tumors, possible causal...

  • The neuropathological basis of clinical progression in multiple sclerosis. Reynolds, Richard; Roncaroli, Federico; Nicholas, Richard; Radotra, Bishan; Gveric, Djordje; Howell, Owain // Acta Neuropathologica;Aug2011, Vol. 122 Issue 2, p155 

    Multiple sclerosis is the major inflammatory condition affecting the central nervous system (CNS) and is characterised by disseminated focal immune-mediated demyelination. Demyelination is accompanied by variable axonal damage and loss and reactive gliosis. It is this pathology that is thought...

  • Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. Vidal-Jordana, Angela; Sastre-Garriga, Jaume; Rovira, Alex; Montalban, Xavier // Journal of Neurology;Dec2015, Vol. 262 Issue 12, p2617 

    Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system with a complex and heterogeneous pathology that may ultimately lead to neurodegeneration and brain atrophy. Brain volume loss in MS is known to occur early in the disease course and to be clinically relevant, as...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics